Loading...

CYTM

GDTC

CYTOMED THERAPEUTICS LTD

(GDTC)

2025 6-K

Show Summary

Summary

Company Expansion

ATM Offering Program

Clinical Trial Update

Share Issuance Approval

Annual Meeting Results

Annual Meeting Notice

Financial Results Update

Collaboration Agreement

Leadership Changes

First Patient Dosed

Clinical Trial Funding

Asset Acquisition

Financial Report Update

Board Restructure

Board Resignation

Annual Shareholders Meeting

Proxy Statement Update

Annual Meeting Notice

Shareholder Cell Banking

Research Partnership

External Links:

On July 21, 2025, CytoMed Therapeutics Ltd announced they completed Dose Level 1 of the ANGELICA Trial and will proceed to Dose Level 2 for their clinical study on advanced solid tumors and hematological malignancies. This is a significant milestone for the company.

AI Assistant

CYTOMED THERAPEUTICS LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.